Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $17000.0.

  • Tg Therapeutics' Depreciation & Amortization (CF) rose 5454.55% to $17000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $47000.0, marking a year-over-year decrease of 5154.64%. This contributed to the annual value of $68000.0 for FY2024, which is 6777.25% down from last year.
  • Tg Therapeutics' Depreciation & Amortization (CF) amounted to $17000.0 in Q3 2025, which was up 5454.55% from $13000.0 recorded in Q2 2025.
  • Tg Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $80000.0 during Q4 2021, with a 5-year trough of $8000.0 in Q1 2025.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $59000.0 (2021), whereas its average is $47473.7.
  • Per our database at Business Quant, Tg Therapeutics' Depreciation & Amortization (CF) surged by 9705.88% in 2021 and then plummeted by 8493.15% in 2024.
  • Quarter analysis of 5 years shows Tg Therapeutics' Depreciation & Amortization (CF) stood at $80000.0 in 2021, then decreased by 8.75% to $73000.0 in 2022, then tumbled by 47.95% to $38000.0 in 2023, then crashed by 76.32% to $9000.0 in 2024, then skyrocketed by 88.89% to $17000.0 in 2025.
  • Its last three reported values are $17000.0 in Q3 2025, $13000.0 for Q2 2025, and $8000.0 during Q1 2025.